Güven ÜSTÜN, Burak TURNA, Kaan AKBAY, Başak DOĞANAVŞARGİL, Bülent SEMERCİ

Kemik metastazı ile tanı konulmuş metastatik renal hücreli karsinom olgusu

Renal hücreli karsinomlu hastaların %30-50'sinde zaman içerisinde metastaz ortaya çıkacaktır. Bu olgu sunumunda kemik metastazı ile tanı alan ve sitoredüktif nefrektomi uygulanan renal hücreli karsinom olgusu sunulmuş ve literatür gözden geçirilmiştir. 69 yaşındaki erkek renal hücreli kanser olgusu; kliniği, görüntüleme yöntemleri ve tedavisi ile birlikte sunulmuştur. Metastatik böbrek tümörlerinde radikal nefrektominin sitokin immünoterapisi ile kombinasyonun sağ kalıma olumlu etkisi olabileceği bildirilmektedir. Uygun hastalarda akıldan çıkarılmaması gereken bir tedavi modalitesidir.

Anahtar Kelimeler:

Neoplazm metastazı, Yaşlı, Kemik neoplazmları, Karsinom, renal hücreli, Erkek, Sağkalım

Ametastatic renal cell carcinoma case diagnosed with bone metastasis

Thirty-fifty percent of patients with renal cell carcinoma will evantuaily develop metastatic disease. In this case report, a male patient who initially presented with bone metastasis was then diagnosed with renal cell carcinoma after cytoreductive nephrectomy, is presented and relevant literature was reviewed. A 69 year old renal cell carcinoma male patient; presentation, diagnosis, relevant tests and management plan is presented. Cytoreductive nephrectomy in conjunction with cytokine therapy in the setting of metastatic disease in renal cell carcinoma may have a role in terms of survival.

Keywords:

Neoplasm Metastasis, Aged, Bone Neoplasms, Carcinoma, Renal Cell, Male, Survival,

PDF

___

Jemal A, Murrey T, Samuels A, et al. Cancer statistics. Cancer J Clin 2003; 53: 5 - 26.
Shvarts O, Lam JS, Kim HL, et al. ECOG performancestatus predicts bone metastasis in patients presenting with RCC: implication for preoperative.bone scans. J Urology 2004; 172: 867-70.
Anselm B, Frank B, Gerary G, et al. Treatment of bone metastasis and local recurrence from RCC with immunochemotherapy and radiation. World J of Urology 2005; 10: 1007-13
Medical Research Council Callaborators. Interferon-a and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet_1999; 353: 14-7.
Minasian LM, Motzer RJ, Gluck L, et al. Interferon alpha-2a in advanced renal cell carcinoma treatment results and survival in 159 patients with long term follow-up. J Clin Oncol_1993; 11: 1368-75.
Montie JE, Stewart BH, Straffon RA, et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117:272-5.
Dekemion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978; 120: 148-42.
Figlin R, Gitlitz B, Fanklin I, et al. lnterleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma. Cancer J Sci Am 1997; 3 Suppl 1: 92-97.
Belldegrun A, Shvarts O, Figlin R. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl 1): 88-92.
FIanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Eng J Med 2001; 1655-59. 11. Mickisch
GH, Garin A, van Poppel H, et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-70.